Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 10/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883546 | 0.92 | CA12 (0.50) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL14817239 | 0.92 | CA12 (0.50) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL7273053 | 0.85 | ALDH1A1 (0.54) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2936686 | 0.84 | ALDH1A1 (0.61) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL8630858 | 0.82 | ALDH1A1 (0.51) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2533902 | 0.81 | MAOA (0.57) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL31139224 | 0.81 | MAOA (0.57) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL11683637 | 0.81 | CA1 (0.50) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL24390595 | 0.81 | ALDH1A1 (0.50) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL4750053 | 0.81 | PLA2G4A (0.51) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2349351-A2 | IMAGING AND RADIOTHERAPY METHODS | GE Healthcare Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | LMNA 3727/4885ALDH1A1 3/4885MAPT 2862/4885 |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | LMNA 3727/4885ALDH1A1 3/4885MAPT 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.